Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review.

Maria Gonzalez SuarezCharat ThongprayoonPanupong HansrivijitKarthik KovvuruSwetha Rani Kanduri Narothama Reddy Aeddula Aleksandra I Pivovarova Api ChewcharatTarun BathiniMichael A Mao Arpita Basu Wisit Cheungpasitporn

Published in: Medical sciences (Basel, Switzerland) (2020)

Our study suggests that the lowest incidence of allograft loss (33%) among KTX patients with C3G are those treated with eculizumab. Among those who received no treatment for C3G due to stable allograft function, there is a high incidence of allograft loss of 32% in C3GN and 53% in DDD. sMAC level may help to select good responders to eculizumab.

Keyphrases

risk factors
combination therapy
replacement therapy
childhood cancer